Resveratrol
What it is
Resveratrol is a polyphenol compound found naturally in the skin of red grapes, certain berries, and peanuts. It is produced by plants in response to stress, injury, and fungal infection. The compound attracted significant scientific and popular attention following observations that it extended lifespan in yeast, worms, flies, and mice, and that it appeared to activate sirtuins, a family of proteins associated with longevity pathways.
The commercial form is trans-resveratrol, typically derived from Japanese knotweed (Polygonum cuspidatum) rather than grape sources, at concentrations many times higher than any dietary intake could provide. This distinction is relevant: the concentrations used in preclinical research and commercial supplements bear little resemblance to those achievable through food.
What the evidence shows
The resveratrol story is one of the most instructive cases in supplement science of how promising preclinical findings can fail to replicate in humans, and of how the commercial narrative can accelerate far ahead of the actual evidence. Where effects are observed in human trials, they are generally small and inconsistently reproduced across studies.
Longevity and lifespan extension in humans has not been demonstrated. The animal data generated enormous excitement but has not translated into human trials of meaningful duration or outcomes. No human trial has assessed longevity endpoints directly, and surrogate markers associated with longevity pathways have shown inconsistent responses.
Cardiovascular protection was one of the most heavily promoted applications. Human trials examining blood pressure, lipids, endothelial function, and inflammatory markers have returned inconsistent results. Some meta-analyses report modest systolic blood pressure reductions at higher doses (above 300mg/day), but these effects are not consistent across trials and do not reach clinical decisiveness.
Metabolic health represents the most modest positive signal in the literature. Some trials in individuals with type 2 diabetes or metabolic syndrome have reported small improvements in insulin sensitivity and fasting glucose, but effect sizes are small, durations short, and replication incomplete.
SIRT1 activation and longevity pathway modulation has not been consistently demonstrated in humans at commercially relevant doses. The current understanding positions resveratrol's effects, where they exist, as likely indirect, potentially AMPK-mediated, rather than as direct SIRT1 activation.
Five questions
Does resveratrol correct a deficiency state?
No. Resveratrol is not an essential nutrient and there is no recognised deficiency state. This question does not apply.
Does supplementation prevent disease in at-risk populations?
No robust evidence supports this. No long-duration prevention trial has been conducted, and no RCTs with hard clinical endpoints such as cardiovascular events or mortality exist. The evidence does not currently support a prevention claim in any population.
Does resveratrol produce meaningful biomarker effects?
Inconsistently and without a clear direction. Results across trials examining blood pressure, lipid profiles, inflammatory markers, endothelial function, and insulin sensitivity are mixed. No biomarker response is consistent enough to serve as a reliable indicator of biological activity at commonly used doses.
Does resveratrol improve outcomes in clinical populations?
There is a modest and inconsistent signal in metabolic populations, particularly individuals with type 2 diabetes or insulin resistance, for small improvements in fasting glucose and insulin sensitivity. This is the most credible clinical signal in the current literature but does not support a broad therapeutic claim.
Does resveratrol benefit healthy, replete adults?
The evidence does not support this. The theoretical longevity and anti-ageing rationale has not translated into demonstrable benefit in healthy populations in any well-conducted human trial.
Individual variation
There is no well-characterised population for whom resveratrol supplementation produces consistent and clinically meaningful benefit. The metabolic signal in individuals with type 2 diabetes and insulin resistance is the closest candidate, but the evidence is too inconsistent and the effect sizes too small to support targeted recommendations at present.
Genetic variation in resveratrol metabolism, particularly CYP1B1 and sulphotransferase activity, may influence bioavailability, but this has not been translated into clinically useful guidance.
Safety
Resveratrol is generally well-tolerated at doses up to 1g/day in short-term trials. GI discomfort is the most commonly reported side effect. At higher doses (2.5g/day and above), reversible elevations in liver enzymes have been reported. Resveratrol inhibits CYP3A4 and CYP2C9 enzymes and may increase plasma concentrations of drugs metabolised by these pathways. In vitro oestrogenic activity warrants caution in oestrogen-sensitive conditions.
What can reasonably be concluded
Resveratrol is a compound with genuine preclinical biological activity that has not translated into consistent, clinically meaningful effects in humans at commercially available doses. The longevity narrative rests almost entirely on animal and cell data. The metabolic signal in diabetes populations is the one area with a weak emerging signal, but it is not robust enough to support targeted supplementation recommendations. Where effects are observed, they are small and inconsistently reproduced.
Where evidence is limited or outcomes are uncertain, conclusions should be treated as provisional and subject to revision as the evidence base develops.